Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
CD40L (human) (multimeric) (rec.)
370
CHF
CHF 370.00
In stock
AG-40B-0010-C01010 µgCHF 370.00
AG-40B-0010-30103 x 10 µgCHF 740.00
Figure 1: CD40L (human) (multimeric) (rec.) (Prod. No. AG-40B-0010) does not need an enhancer to induce B cells activation.
Method: PBL cells were incubated in 96-well plates (2x105 cells/well in 100μl RPMI supplemented with 10% FCS) for 24 hours at 37°C with the indicated concentration of CD40L (human) (multimeric) (rec.) or CD40L (h) in the presence and absence of 1μg/ml Enhancer (Prod. No AG-35B-0001). Cells were washed with PBS and stained with 2 μl each CD86-PE and CD19-FITC in 50μl FACS buffer (PBS, 5% fetal calf serum, 0.02% azide) for 20 min. at 4°C in the dark. After two washes in FACS buffer, samples were then analyzed by flow cytometry.
Method: PBL cells were incubated in 96-well plates (2x105 cells/well in 100μl RPMI supplemented with 10% FCS) for 24 hours at 37°C with the indicated concentration of CD40L (human) (multimeric) (rec.) or CD40L (h) in the presence and absence of 1μg/ml Enhancer (Prod. No AG-35B-0001). Cells were washed with PBS and stained with 2 μl each CD86-PE and CD19-FITC in 50μl FACS buffer (PBS, 5% fetal calf serum, 0.02% azide) for 20 min. at 4°C in the dark. After two washes in FACS buffer, samples were then analyzed by flow cytometry.
| Product Details | |
|---|---|
| Synonyms | MultimericCD40L™; ACRP30headless:CD40L; ACRP30headless:CD154; ACRP30headless:TNFSF5; ADIPOQ-CD40L |
| Product Type | Protein |
| Properties | |
| Source/Host | CHO cells |
| Sequence |
Human CD40L (aa 116-261) is fused at the N-terminus to mouse ACRP30headless (aa 18-111) and a FLAG®-tag. |
| Crossreactivity | Human |
| Specificity |
Binds to human CD40. |
| Biological Activity |
Induces B cells activation (as demonstrated by dose-dependent upregulation of CD86) (ED50: <1ng/ml). B cell expansion online protocol available. |
| MW | ~35-40kDa (SDS-PAGE) |
| Purity | ≥95% (SDS-PAGE) |
| Endotoxin Content | <0.01EU/μg purified protein (LAL test, Lonza). |
| Concentration | 0.1mg/ml after reconstitution. |
| Reconstitution | Reconstitute with 100μl sterile water. |
| Formulation | Lyophilized. Contains PBS |
| Other Product Data |
UniProt link P29965: CD40L (human) FLAG is a registered trademark of Sigma-Aldrich Co. |
| Shipping and Handling | |
| Shipping | BLUE ICE |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
After reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. Centrifuge lyophilized vial before opening and reconstitution. PBS containing at least 0.1% BSA should be used for further dilutions. |
| Use/Stability |
Stable for at least 6 months after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C. |
| Documents | |
| Protocols |
 Download PDF |
| MSDS |
Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
MultimericCD40L™ is a high activity construct in which two trimeric CD40 ligands are artificially linked via the collagen domain of ACRP30. This construct very effectively simulates the natural membrane-assisted aggregation of CD40L in vivo. It provides a simple and equally potent alternative to [CD40L+enhancer] combinations. MultimericCD40L™ has shown to suppress alum-induced IL-1β release and caspase-1 activation in a dose-, CD40- and time dependent manner, without affecting BMDM viability. It also effectively suppressed the inflammasome function triggered by NLRP3 activators. The secretion of caspase-1 independent inflammatory mediators has been shown to be unaltered or even enhanced.
Product References
- IgG subclass switch capacity is low in switched and in IgM-only, but high in IgD+IgM+, post-germinal center (CD27+) human B cells: C. Werner-Favre, et al.; Eur. J. Immunol. 31, 243 (2001)
- Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex: N. Holler, et al.; Mol. Cell. Biol. 23, 1428 (2003)
- Impaired CD40L signaling is a cause of defective IL-12 and TNF-alpha production in Sezary syndrome: circumvention by hexameric soluble CD40L: L.E. French, et al.; Blood 105, 219 (2005)
- Cysteine-rich Domain 1 of CD40 Mediates Receptor Self-assembly: C.R. Smulski, et al.; J. Biol. Chem. 288, 10914 (2013)
- Sensitive, multiplex and direct quantification of RNA sequences using a modified RASL assay: H.B. Larman, et al.; Nucl. Acids Res. 42, 9146 (2014)
- CD4+ T Cell-derived IL-21 and deprivation of CD40 signaling favor the In Vivo development of granzyme B-expressing regulatory B cells in HIV patients: C. Kaltenmeier, et al.; J. Immunol. 194, 3768 (2015)
- Lenalidomide potentiates CD4+ CD25+ Treg-related suppression of lymphoma B-cell proliferation: M.A. Grygorowicz, et al.; Clin. Exp. Med. 17, 193 (2017)
- CRISPR/Cas9 Screens Reveal Multiple Layers of B cell CD40 Regulation: Ch. Jiang, et al.; Cell Rep. 28, 1307 (2019)
- Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes: J. Racle, et al.; Nat. Biotech. 37, 1283 (2019)
- Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes: C. Chong, et al.; Nat. Commun. 11, 1293 (2020)
- Biogenesis of HLA Ligand Presentation in Immune Cells Upon Activation Reveals Changes in Peptide Length Preference: F. Marino, et al.; Front. Immunol. 11, 1981 (2020)
- Detection of alloreactive T cells from cryopreserved human peripheral blood mononuclear cells: N. Tanimine, et al.; J. Immunol. Meth. 491, 112987 (2021)
- Sensitive identification of neoantigens and cognate TCRs in human solid tumors: M. Arnaud, et al.; Nat. Biotechnol. 40, 656 (2022)
Related Products
